ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cadonilimab

Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.

Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.

Drug pageCadonilimab: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 21, 202145 company-led studies, 22 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso4219 open or runningphase 3since Jul 21, 2021Aug 20, 2017Nov 2026phase 3 · NCT06341335
RemeGenits history only11 open or runningphase 3since Jan 15, 2024Jan 15, 2024Dec 2026phase 3 · NCT06221748
Shanghai Pharmaceuticalsits history only11 open or runningphase 2since Jul 6, 2023Jul 6, 2023Dec 31, 2026phase 2 · NCT05944224
Summit Therapeuticsits history only11 open or runningphase 2since Sep 29, 2026Sep 29, 2026Apr 12, 2029phase 2 · NCT07877194

Also a collaborator on its studies: Chipscreen Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Akeso only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 29 earlier studies, Aug 20, 2017 to Jun 27, 2023.

  1. Dec 19, 2020Named cadonilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AK104
  2. Aug 3, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05990127 · 642 planned · China
  3. Mar 26, 2024Phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaNCT06341335 · 506 planned · China
  4. Apr 15, 2024Phase 3 study in Carcinoma, HepatocellularNCT06371157 · 469 planned · China
  5. Aug 15, 2024Phase 2 study in Ovarian NeoplasmsNCT06560112 · 172 planned · China
  6. Sep 25, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06617416 · 560 planned · China
  7. Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055 · 110 enrolled · China
  8. May 15, 2025Phase 2 study in Carcinoma, HepatocellularNCT06984718 · 120 planned
  9. Jun 10, 2025Phase 3 study in AdenocarcinomaNCT07023315 · 760 planned · China
  10. Nov 24, 2025Phase 2 study in Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaNCT07263919 · 90 planned · China
  11. Feb 9, 20262 phase 3 studiesNCT07412613, NCT07449780
  12. May 26, 2026Phase 1 study in Healthy Male Adults ParticipantsNCT07619001 · 158 planned · China
  13. Jul 8, 2026Phase 3 study in Stomach NeoplasmsNCT07700979 · 900 planned · United States, China, Germany and more
  14. Sep 28, 2026Phase 2 study terminatedStudy stoppedNCT05932212 · “Sponsor decision”
  15. Nov 12, 2026Primary completion moved from 2026-11-05 to 2028-06-30Date moved laterphase 1 · +20 months · NCT06929663

Ahead

  1. Nov 2026Primary completion: phase 3 study in Gastric and Gastroesophageal Junction AdenocarcinomaNCT06341335
  2. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06984718
  3. Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055
  4. Apr 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05142423

TargetBeta

CTLA4 →PDCD1 →read by rule
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 42 Akeso leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700979Stomach Neoplasms · United States, China, Germany and more3RecruitingAug 18, 2029900
NCT07619001Healthy Male Adults Participants · China1Not yet recruitingSep 30, 2026158
NCT07449780Gastric / Gastroesophageal Junction Adenocarcinoma3Not yet recruitingNov 17, 2027422
NCT07412613Resectable Colon Cancer · China3RecruitingJun 15, 2030386
NCT07263919Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · China2RecruitingMar 203090
NCT07023315Adenocarcinoma · China3RecruitingJul 2029760
NCT06984718Carcinoma, Hepatocellular2Not yet recruitingNov 30, 2026120
NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China2Active, not recruitingDec 30, 2026110
NCT06617416Carcinoma, Non-Small-Cell Lung · China3RecruitingOct 28, 2026560
NCT06560112Ovarian Neoplasms · China2RecruitingMay 1, 2026172
NCT06371157Carcinoma, Hepatocellular · China3RecruitingOct 25, 2025469
NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma · China3RecruitingNov 2026506
NCT05990127Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingAug 5, 2025642
NCT05932212Vulvar Neoplasms · China2TerminatedMay 31, 202620
NCT05904379Advanced Non-small-cell Lung Cancer · China2Active, not recruitingJun 30, 2026233
NCT05559554Healthy Male Subjects · China1CompletedMar 24, 2023100
NCT05559541Solid Tumor, Adult · China2TerminatedMay 31, 202433
NCT05505825SCLC,Extensive Stage · Australia, China2CompletedJul 19, 202436
NCT05489289Carcinoma, Hepatocellular · China3RecruitingJan 28, 2026570
NCT05319431Unresectable, Non-metastatic Hepatocellular Carcinoma · China2Active, not recruitingAug 15, 202360
NCT05227651Uterine Cervical Neoplasms · China2CompletedSep 27, 202414
NCT05235542Advanced Malignant Tumors · China2CompletedMay 9, 2026128
NCT05256472Carcinoma, Renal Cell · China2CompletedDec 31, 202528
NCT05235516Locally Advanced Cervical Carcinoma · China3Active, not recruitingMay 2026636
NCT05215067Advanced Non-small Cell Lung Cancer · China2CompletedJan 30, 202644
NCT05142423Advanced Solid Tumor · China2RecruitingApr 2027198
NCT05021120Advanced or Metastatic Solid Tumours · AustraliaEarly 1CompletedOct 1, 202467
NCT05008783Gastric Adenocarcinoma · China3CompletedDec 6, 2024610
NCT04982237Uterine Cervical Neoplasms · China3Active, not recruitingDec 30, 2025445
NCT04868708Recurrence · China2CompletedFeb 28, 202450
NCT04728321Carcinoma, Hepatocellular · China2CompletedAug 2, 202232
NCT04646330NSCLC · China2CompletedOct 26, 2023114
NCT04647344Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV · China2CompletedDec 31, 202346
NCT04572152Advanced or Metastatic Solid Tumors · Australia1CompletedMay 2, 202323
NCT04547101MSI-H/dMMR Solid Tumor · China2TerminatedSep 30, 20226
NCT04444167Carcinoma, Hepatocellular · China2CompletedNov 20, 202359
NCT04444141Lymphoma, T-Cell, Peripheral · China2TerminatedSep 30, 20226
NCT04380805Uterine Cervical Neoplasms · United States, Australia, New Zealand2CompletedDec 22, 202230
NCT04220307Nasopharyngeal Carcinoma · China2CompletedMay 15, 202134
NCT04172454Melanoma · China2CompletedJun 17, 202168
NCT03852251Diabetes Mellitus, Insulin-Dependent, 12 · China2CompletedMar 25, 2024338
NCT03261011Advanced Cancer · Australia1CompletedAug 27, 2021119

How it is read

Names in the registry

  • “AK104”, 26 entries
  • “Cadonilimab”, 3 entries
  • “Cadonilimab (AK104)”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK104+anlotinib”, 3 entries

Codes read as this program: AK104.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.